Incyte Business Segments — Other research and development decreased by 81.9% to $12.60M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 18.7%, from $15.50M to $12.60M. Over 3 years (FY 2022 to FY 2025), Business Segments — Other research and development shows a downward trend with a -8.2% CAGR.
High volatility here often signals one-time licensing deals or strategic shifts in the R&D pipeline.
This category captures non-recurring or miscellaneous R&D expenses that do not fall under standard internal or external...
Varies significantly by company based on their specific accounting for licensing and milestone payments.
incy_segment_reportable_segment_other_research_and_development| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $31.49M | $31.49M | $31.49M | $31.49M | $9.16M | $9.16M | $9.16M | $9.16M | $1.00M | $679.80M | $100.00M | $3.00M | $15.50M | $12.55M | $100.00K | $69.42M | $12.60M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -70.9% | +0.0% | +0.0% | +0.0% | -89.1% | >999% | -85.3% | -97.0% | +416.8% | -19.0% | -99.2% | >999% | -81.9% |
| YoY Change | — | — | — | — | -70.9% | -70.9% | -70.9% | -70.9% | -89.1% | >999% | +991.4% | -67.3% | >999% | -98.2% | -99.9% | >999% | -18.7% |